Research programme: E2F-targeting anticancer therapeutics - TopoTargetAlternative Names: E2F research programme - TopoTarget; E2F-targeting anticancer therapeutics research programme - TopoTarget
Latest Information Update: 10 Jul 2009
At a glance
- Originator TopoTarget
- Class Small molecules
- Mechanism of Action Genetic transcription inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Jul 2009 Discontinued - Preclinical for Cancer in Denmark (unspecified route)
- 10 Jul 2009 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 23 Jan 2004 Suspended - Preclinical for Cancer in United Kingdom (unspecified route)